03:53 AM EDT, 09/30/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Sunday two sets of data from a phase 3 study showed that its vutrisiran investigational drug for treatment for ATTR amyloidosis with cardiomyopathy slowed disease progression.

The illness causes a gradual thickening of the cardiac wall and a deterioration in heart functions leading to possible cardiac stress.

The study of 654 patients showed the drug candidate slowed disease progression compared with placebo after 30 months, the company said.

"Significant improvements in both diastolic and systolic function were observed as early as 12 months and 18 months, respectively, in the overall population," Alnylam said.